Interestingly, previous studies reported that that disrupting myeloid cell recruitment by jointly blocking CXCR2 and CCR2 could enhance anti-tumor immunity and therapeutic responses in pancreatic cancer models [39]. Here, CXCR2 is linked to neoplasm.